Compare ARVN & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | TLRY |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 560.3M |
| IPO Year | 2018 | 2018 |
| Metric | ARVN | TLRY |
|---|---|---|
| Price | $8.27 | $3.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | $15.05 | ★ $72.33 |
| AVG Volume (30 Days) | 711.6K | ★ 3.3M |
| Earning Date | 05-04-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | 55.69 |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | N/A | $19.98 |
| P/E Ratio | $4.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.97 | $0.77 |
| 52 Week High | $14.22 | $15.70 |
| Indicator | ARVN | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 33.64 |
| Support Level | $7.90 | $3.67 |
| Resistance Level | $8.40 | $4.91 |
| Average True Range (ATR) | 0.32 | 0.17 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 11.88 | 8.02 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Tilray is as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. The company portfolio includes brand such as Sweet Water Brewing, Montauk Brewing, Brew Dog, Shock Top, 10 Barrell, Breckenridge Brewery, Blue Point Brewing, Breckenridge Distillery, Revolver, Terrapin, Broken Coast, Good Supply, Redecan, Solei, Tilray, ARX, XMG, Manitoba Harvest and Hi-Ball. The company has four segment Beverage, Cannabis, Distribution and Wellness. The majority of the revenue is generated from Distribution business which encompasses the purchase and resale of pharmaceuticals products to customers.